Recent analyst reports highlight a more positive earnings outlook for AbCellera Biologics (ABCL). This coincides with the stock outperforming the broader Medical sector and its peers this year, which has influenced sentiment around its recent move.

The recent 1 month share price return of 45.82% and 90 day share price return of 74.12% suggest momentum has been building, even though the 3 year total shareholder return is slightly down while the 1 year total shareholder return is very strong.

If this kind of sharp move has you looking beyond a single stock, it could be a good moment to scan for other promising healthcare AI opportunities using our 40 healthcare AI stocks

With AbCellera up sharply in recent months and trading at a discount of about 61% to the average analyst price target of US$10.43, an important question arises: Is there still a buying opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 34.3% Undervalued

AbCellera's most followed valuation narrative puts fair value at $9.83 per share, well above the last close of $6.46, which is driving interest in the upside case.

The initiation of Phase I clinical trials for ABCL635 and ABCL575, with promising differentiation factors such as a unique dosing regimen and improved safety profile for ABCL635, is expected to position the company to capture a significant market opportunity in an underserved area, potentially boosting future revenue.

AbCellera's transition from a platform company to a clinical-stage biotech, along with the development of internal programs, suggests a shift towards generating revenue from downstream milestone fees and royalty payments as new molecules are expected to reach the clinic.

Want to see what is behind that valuation gap? The narrative focuses on ambitious revenue ramps, margin expansion, and a future earnings multiple usually reserved for market favorites.

The fair value estimate is built on a discount rate of 7.82%, assumptions of fast revenue growth, improving profit margins, and a very rich future P/E multiple relative to the US Life Sciences industry. That combination, together with expectations for downstream milestone and royalty income, is what underpins the conclusion that the stock is trading at a 34.3% discount to fair value.

Result: Fair Value of $9.83 (UNDERVALUED)

However, you still need to weigh the widening net loss alongside intense competition around ABCL635 and uncertainty over partnered assets, which could challenge this upbeat valuation story.

Another Angle: What The Sales Multiple Is Telling You

The fair value story built around long term earnings and margins paints AbCellera as 34.3% undervalued, but the current pricing on sales points the other way. The stock trades on a P/S of 24.9x, compared with 3.9x for the US Life Sciences industry and 8.3x for peers, while the fair ratio sits at just 0.3x.

That gap is very wide, which means a lot of future success already needs to show up in the numbers for today’s price to hold. The question for you is whether the clinical pipeline and royalty potential truly justify such a premium, or if expectations have run ahead of the fundamentals.

Next Steps

Mixed messages in the story so far? With both risks and rewards on the table, move quickly to review the data and weigh the 1 key reward and 2 important warning signs.

Looking for more investment ideas?

AbCellera might be on your radar already, but you do not want your next move to depend on a single stock. Let the data surface other candidates.

• Spot potential mispriced opportunities by scanning a curated list of companies that look inexpensive on quality metrics using our 47 high quality undervalued stocks
• Prioritize resilience and sleep-better-at-night holdings by checking companies that pass balance sheet and fundamentals checks through the solid balance sheet and fundamentals stocks screener (45 results)
• Get ahead of the crowd by reviewing a screener containing 22 high quality undiscovered gems that might not be widely followed yet but still show strong underlying numbers

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.